Browse diseases

…) for lung cancer, nine (10.0%) for leukaemia, eight (8.9%) for urothelial carcinoma, and six (6.7%) for breast cancer ( table 1, online supplementa…

…ent goals and be acceptable to regulatory and HTA bodies. Thus, lymphoma clinical trials can generate more patient-focused data, contrib…

…moderate validity in AL (r=0.386, p=0.002) and poor validity in lymphoma (r=0.230, p=0.129). In patients with AL, chronic kidney failure…

…9) CAR-T cells as well as anti-CD20 bispecific antibodies, with lymphoma cells resulting in CD19 and CD20 antigen loss.Conclusions This …

…nausea and laboratory parameters.Conclusions Patients receiving lymphoma chemotherapy exhibited various symptoms manifesting as four dis…

…cluding late events and inform risk prediction in patients with lymphoma and myeloma receiving novel immunotherapies.Methods and analysi…

…BUS were performed with 3891 samples taken, including suspected lung cancer (n=2463), suspected metastatic disease (n=376), isolated medias…

…feration and expansion, no features of CAEBV and no evidence of lymphoma. EBV serology testing was immunoglobulin G positive but immunog…

…n the same-day arm than in the next-day group for patients with breast cancer (OR=5.50, 95% CI 2.29 to 13.23, p=0.0001) and lymphoma (OR=1.53…

…h large pelvic tumours and the importance of considering pelvic lymphoma as a possible differential diagnosis.…

…n diseases, sarcoidosis and lymphoma but similar performance in lung cancer. Most adverse events were mild to moderate, although EBUS-TMC h…

… lung/respiratory cancer (pooled OR 0.86, 95% CI 0.67-1.09), or thyroid cancer (pooled OR 1.42, 95% CI 0.23-8.66). Most outcomes showed modera…